A corporate venture arm of a leading global Contract Research, Development and Manufacturing Organization (CRDMO) founded in 2018 is open to investing in anywhere from seed to IPO financing rounds. Initial investment size can vary and follow-on investment is possible. The firm primarily seeks opportunities in the US, and is open to China and Europe as well. The venture arm does not lead rounds and prefers companies with a lead investor in place. Depending on the investment size and deal terms, the fund may consider an observer seat or board seat. The venture arm makes equity investments only and does not have an equity-for-service model.
Separately from the corporate venture arm, the organizations runs a program that collaborates with over 25 partners, such as accelerators, seed/venture capital firms, incubators, and other similar programs to provide startups various tools and resources to accelerate biologics and vaccine development, including credits for the organization’s technology platforms. Startups must be an active participant or referred by a Program Partner to be eligible.
The venture arm will consider a wide range of biotech assets, from antibody drug, protein therapeutics, vaccines, DNA and mRNA drugs. The fund is also open to orphan drugs. One type of asset that the fund does not consider cell and gene therapy.
The venture arm does not lead rounds therefore would only invest when a lead investor is secured. The fund is open to working with new or first time founders but hopes to see that the team has a good supportive network. The fund is interested in working with founders who are open to advice and suggestions.
The venture’s team is open to meeting with companies in their initial stage of fundraising and will track their progress. But they will only look deeper into the opportunities when a lead investor is in play and the company is close to signing a term sheet.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment